IRIDEX
ProfileJobs

IRIDEX

Suggest Edit
    • HealthTechnologylasersmedical devices
    A worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 60 independent distributors into over 100 countries.
    Revenue(FY, 2017)
    $41.6 M
    Market capitalization(2018-04-23)
    $67.6 M
    Type
    Public
    HQ
    Mountain View, US
    Founded
    1989
    Size (employees)
    121 (est)+13%
    Website
    iridex.com
    IRIDEX was founded in 1989 and is headquartered in Mountain View, US
    Report incorrect company information

    IRIDEX Office Locations

    IRIDEX has an office in Mountain View
    Mountain View, US (HQ)
    1212 Terra Bella Ave
    Show all (1)
    Report incorrect company information

    IRIDEX Financials and Metrics

    IRIDEX Financials

    IRIDEX's revenue was reported to be $41.59 m in FY, 2017
    USD

    Revenue (FY, 2017)

    		41.6 m

    Gross profit (FY, 2017)

    		15.5 m

    Gross profit margin (FY, 2017), %

    		37.3%

    Net income (FY, 2017)

    		(12.9 m)

    EBIT (FY, 2017)

    		(12.9 m)

    Market capitalization (23-Apr-2018)

    		67.6 m

    Cash (30-Dec-2017)

    		21.7 m
    IRIDEX's current market capitalization is $67.6 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		38.3 m42.8 m41.8 m46.2 m41.6 m

    Revenue growth, %

    		12%(2%)11%

    Cost of goods sold

    		19.7 m21.4 m21.8 m25.3 m26.1 m

    Gross profit

    		18.6 m21.4 m20 m20.8 m15.5 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017

    Revenue

    		9.5 m10.3 m10.6 m10.1 m9.8 m10.8 m9 m9.8 m11.9 m11.9 m10.5 m10 m

    Cost of goods sold

    		4.8 m5.3 m5.3 m5 m5 m5.4 m4.8 m5.5 m6.6 m6.2 m6 m5.5 m

    Gross profit

    		4.7 m5.1 m5.3 m5.1 m4.8 m5.4 m4.2 m4.2 m5.3 m5.7 m4.5 m4.5 m

    Gross profit Margin, %

    		50%49%50%51%49%50%47%43%44%48%43%45%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		13.4 m13.3 m10 m23.7 m21.7 m

    Inventories

    		10.6 m9.1 m11.1 m11.6 m9.4 m

    Current Assets

    		32 m32.9 m30.8 m45.9 m39.5 m

    PP&E

    		543 k735 k1.1 m1.5 m1.4 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017

    Cash

    		14.1 m14 m12.9 m13 m10.2 m13.1 m12.2 m9.6 m10.5 m11.5 m23.9 m24.6 m

    Inventories

    		10 m9.9 m9.8 m9.6 m11.2 m9.9 m10.2 m12.7 m11.1 m12.1 m11.7 m11.4 m

    Current Assets

    		30.4 m31.3 m30.5 m30.8 m31.4 m33.2 m31.9 m31.4 m31.4 m32.7 m45 m43.5 m

    PP&E

    		526 k575 k720 k748 k1.1 m1 m1.1 m1.4 m1.1 m1.2 m1.7 m1.6 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		2.2 m10 m474 k(11.7 m)(12.9 m)

    Depreciation and Amortization

    		490 k420 k522 k648 k858 k

    Inventories

    		(2.5 m)1.5 m(2 m)(537 k)2.1 m

    Accounts Payable

    		173 k(520 k)465 k(229 k)(270 k)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017

    Net Income

    		530 k487 k297 k490 k442 k246 k(652 k)(671 k)101 k(328 k)(1.9 m)

    Inventories

    		9.8 m9.6 m11.2 m9.9 m10.2 m12.7 m11.1 m12.1 m11.7 m

    Accounts Payable

    		2 m1.8 m2.6 m2.5 m2.1 m2.5 m2.7 m3.2 m1.9 m
    show all
    USDY, 2017

    Revenue/Employee

    		363.3 k

    Financial Leverage

    		1.4 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Tangen Biosciences
    Health - Private
    Neovasc
    Health - Public
    Ellipse Technologies
    Health - Subsidiary
    LensAR
    Health - Subsidiary
    Compare competitors

    IRIDEX News and Updates

    January 30, 2018

    International Laser Therapy Market 2018 | Financial Business Overview | Industry Growth Rate and Forecasts by 2023

    The Global Laser Therapy Market is expected to grow at a CAGR of 9.2% during the forecast period. Laser Therapy industry is segmented into dermatology and aesthetics, surgery, dental, and others. The surgery segment is further segmented into urology, ophthalmology and others. Posted via Industry Tod…
    Report incorrect company information
    Download PDF